Fibrate therapy may lower the risks of mortality and progression to end-stage kidney disease (ESKD), despite raising the risk for new onset stage 3 or higher chronic kidney disease (CKD), a new study ...

Residual nodal disease following neoadjuvant chemotherapy for upper tract urothelial carcinoma (UTUC) indicates an especially high-risk population.

Although recommended, many patients with metastatic clear cell RCC still don’t receive immune checkpoint inhibitor-based combinations as first-line treatment.

There are currently no proven therapies that reduce cisplatin-induced acute kidney injury (AKI) in patients with cancer.

There have been no prospective studies comparing stent use vs nonuse after ureteroscopy for uncomplicated renal stones.

The HUGO robotic-assisted surgery system showed a high surgical success rate and favorable rates of grade 3 complications.

Semaglutide improved maximum walking distance in patients with type 2 diabetes and symptomatic peripheral artery disease.

Cancer drugs conferring low or no therapeutic benefits accounted for $6.7 billion in post-rebate Medicare spending in 2022.

Older patients have divergent immune phenotypes at baseline that persist during immune checkpoint inhibitor therapy.

An investigator reported updated findings from the phase 2/3 study QUILT 3.032 using a July 15, 2024 data cutoff.

BOND-003 evaluated the efficacy and safety of cretostimogene grenadenorepvec, an oncolytic immunotherapy, in patients with carcinoma in situ BCG-unresponsive NMIBC.

The ongoing phase 2b SunRISe-1 study is assessing TAR-200 intravesical gemcitabine delivery in patients with BCG-unresponsive high-risk NMIBC.